Margaret A. Tempero, MD

Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF

Cancer Center Program Membership

Molecular Oncology

Research Summary

I am Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program. My research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. I was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. My group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. I directed the first GI SPORE devoted to pancreatic cancer when I was on the faculty of the University of Nebraska and subsequently led the NCI-funded U54 Molecular Target Assessment Team at UCSF. I also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. I have served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. I also serve as co-chair on the Pancreas Task Force Tissue Acquisition Working Group for the NCI intergroup and co-organized the State of the Science meeting on pancreatic cancer at the NCI.

I have extensive experience in scientific review and administration, training and oversight. I co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for three years and spent nine years of service teaching this course and similar courses in Europe and Australia. I was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (two-year term) of the NCI Board of Scientific Counselors Subcommittee A. I am on the External Advisory Boards of the Pancreas SPORE at the University of Alabama in Birmingham/University of Minnesota and the Mayo Clinic.

I am, or have been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. I have held many appointments at AACR and ASCO and served as a member of the ASCO Board of Directors and as ASCO President in 2004. I served as a member of the Oncology Drug Advisory Committee for the FDA from 2007-2011. I served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, and Chief of the Division of Medical Oncology at UCSF (2000-2007) and Deputy Director and Director of Research Programs at the HDFCCC from 2000 to 2012.

Research Funding

  • July 1, 1984 - August 31, 2026 - Buffett Cancer Center Support Grant , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA036727
  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103
  • September 15, 2014 - August 31, 2018 - Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21CA184429
  • September 26, 2001 - December 31, 2008 - Mechanism-Based Evaluations of ErbB-Targeted Agents , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U54CA090788


Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology

Honors & Awards

  • Editor-In-Chief, Journal Nat'l Comprehensive Cancer Network, 2014-Pres
  • Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF, 2012-Pres
  • Doris and Don Fisher Distinguished Professor in Clinical Research, UCSF, 2000-2012

Selected Publications

  1. Tempero M. Understanding Cancer Risk-Genes Matter! J Natl Compr Canc Netw. 2023 09; 21(9):893.  View on PubMed
  2. Tempero M. Being Sick Isn't Easy. J Natl Compr Canc Netw. 2023 Aug; 21(8):785.  View on PubMed
  3. Tempero M. A Glimpse Into the Future. J Natl Compr Canc Netw. 2023 Jul; 21(7):687.  View on PubMed
  4. Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 07; 21(7):753-782.  View on PubMed
  5. Tempero M. "The Times They Are A-Changin' ". J Natl Compr Canc Netw. 2023 Jun; 21(6):587.  View on PubMed
  6. Tempero M. Clinical Trials: Does One Size Really Fit All? J Natl Compr Canc Netw. 2023 May; 21(5):433.  View on PubMed
  7. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023 06 01; 41(16):3063-3071.  View on PubMed
  8. Tempero M. I'm Getting Better at This! J Natl Compr Canc Netw. 2023 Apr; 21(4):335.  View on PubMed
  9. Tempero M. Dying in the Queue and Where Is My Nurse? J Natl Compr Canc Netw. 2023 Mar; 21(3):231.  View on PubMed
  10. Tempero M. Your Words Mean Something! J Natl Compr Canc Netw. 2023 Feb; 21(2):101.  View on PubMed
  11. Tempero M. Another New Beginning. J Natl Compr Canc Netw. 2023 Jan; 21(1):1.  View on PubMed
  12. Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J, Sivagnanam S, Cheung A, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Ware C, Bridge M, Vo J, Dragomanovich H, Sudduth-Klinger J, Vaccaro G, Lopez CD, Tempero M, Coussens LM, Fong L. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. J Immunother Cancer. 2023 01; 11(1).  View on PubMed
  13. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M, APACT Investigators. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 04 10; 41(11):2007-2019.  View on PubMed
  14. Tempero M. Letter to Santa. J Natl Compr Canc Netw. 2022 Dec; 20(12):1279.  View on PubMed
  15. Tempero M. Welcome Aboard! J Natl Compr Canc Netw. 2022 11; 20(11):1189.  View on PubMed
  16. Seufferlein T, Uhl W, Kornmann M, Algül H, Friess H, König A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023 01; 34(1):91-100.  View on PubMed
  17. Tempero M. We Are Winning This War! J Natl Compr Canc Netw. 2022 10; 20(10):1073.  View on PubMed
  18. Tempero M. Together Again! J Natl Compr Canc Netw. 2022 09; 20(9):965.  View on PubMed
  19. Tempero M. My Report Card. J Natl Compr Canc Netw. 2022 08; 20(8):853.  View on PubMed
  20. Tempero M. Failure Doesn't Feel Good! J Natl Compr Canc Netw. 2022 07; 20(7):737.  View on PubMed

Go to UCSF Profiles, powered by CTSI